0

Close
 
Upcoming Allied Market Research
2023
In Vitro Lung Model Market

In Vitro Lung Model Market: Global Opportunity Analysis and Industry Forecast 2023-2030 Market

LS : Diagnostics and Biotech
Report Code: A10203
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the In Vitro Lung Model Market

Request Now !

The human lung is a very delicate organ that functions as an entry and exit of the exchange of gases. Hence, the process of aerosolized materials entry concerning the lung cells is a very well focused and researched field of human health. Disorders in lung diseases affect the function and structure of the lung can cause lethal effects. Generally, animal models are used for the lung disorder analysis and the development of the lung diseases. On the contrary, animal models are not fully to replicate the human lung disease and the development processes, or spotlighting an area of the lung complements with the human to understand the pathological mechanism and the developments.

In-Vitro-Lung-Model-Market

Although there have been many negative effects, animal testing is very prevalent and used for the study of various diseases, risk assessment, and new drug development. In-vitro lung model are made by macrophages culturing, dendritic cells favorable medium culture, and epithelial cells.

COVID-19 scenario analysis:

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicines supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are short of these drugs. Owing to the demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future.
Owing to such factors, COVID 19 is expected to have a significant impact on the In Vitro Lung Model market.

Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact Analysis:

The focus has been shifting from animal testing models to finding out new alternatives, upgrades in the technology of cell culture, along with the development of new 3D in vitro models, are favoring the factors of the in-vitro lung model market.

Additionally, investments and funding for the development of product and research purposes, advancements in 3D cell culture technology, innovative technology in the 3D in vitro models are some of the other factors propelling the growth of the in vitro lung model market.

On the other hand, the scarcity of skilled professionals like technicians and researchers needed for setting up the experiments and their processes which includes complex in vitro models is the biggest challenge faced in the in vitro lung model market.

New product launches and acquisitions to flourish the market:

On June 13th, 2018, InSphero AG, announced that they have received USD 10 million for their research on discovery platforms for cancer and metabolic diseases. InSphero AG is an innovator and a provider of 3D cell-based platforms in efficacy testing and drug discovery.

On September 26th, 2018, The US patent office received a patent for their lung-on-chip system, AlveoliX which will be assisting in drug candidates development for diseases related to the lungs.

Surge in usage in Pharmaceutical and Biotechnology companies applications:

Biotechnology and Pharmaceutical companies, Contract research organizations, and academic and government research institutes are the major consumers of the in-vitro lug model market. Amongst them, the life-science companies are the biggest end-users of the market. 

Key benefits of the report:

  • This study presents the analytical depiction of the global In Vitro Lung Model industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global In Vitro Lung Model market share.
  • The current market is quantitatively analyzed to highlight the global market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed global In Vitro Lung Model market analysis based on competitive intensity and how the competition will take shape in coming years.

Questions answered in the In Vitro Lung Model Market research report:

  • What are the leading market players active in the In Vitro Lung Model market?
  • What the current trends will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities in the market?
  • What are the projections for the future that would help in taking further strategic steps?

 In Vitro Lung Model Market: Global Opportunity Analysis and Industry Forecast 2020–2027 Report Highlights

Aspects Details
By Type
  • 2D Models
  • 3D Models
    • In-house 3D Models
    • Commercialized 3D Models
By   Application
  • Applications of 2D Models
    • Drug Discovery and Toxicology
    • 3D Model Development
    • Basic Research
  • Applications of 3D Models
    • Drug Discovery and Toxicology
    • Physiological Research
    • Stem Cell Research and Regenerative Medicine
By End Users
  • Pharmaceutical and Biotechnology companies
  • Academic and government research institutes
  • Contract research organizations (CROs)
  • Others
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players ATCC, Epithelix, MatTek Corporation, Thermo Fisher Scientific Inc, Merck KGaA, Emulate, AlveoliX, InSphero, Lonza, PromoCell GmbH
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: IN VITRO LUNG MODEL MARKET, BY TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Type

    • 4.2. 2D Models

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. 3D Models

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

      • 4.3.4. In-house 3D Models

        • 4.3.4.1. Market Size and Forecast

      • 4.3.4. Commercialized 3D Models

        • 4.3.4.1. Market Size and Forecast

  • CHAPTER 5: IN VITRO LUNG MODEL MARKET, BY   APPLICATION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By   Application

    • 5.2. Applications Of 2D Models

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

      • 5.2.4. Drug Discovery and Toxicology

        • 5.2.4.1. Market Size and Forecast

      • 5.2.4. 3D Model Development

        • 5.2.4.1. Market Size and Forecast

      • 5.2.4. Basic Research

        • 5.2.4.1. Market Size and Forecast

    • 5.3. Applications Of 3D Models

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

      • 5.3.4. Drug Discovery and Toxicology

        • 5.3.4.1. Market Size and Forecast

      • 5.3.4. Physiological Research

        • 5.3.4.1. Market Size and Forecast

      • 5.3.4. Stem Cell Research and Regenerative Medicine

        • 5.3.4.1. Market Size and Forecast

  • CHAPTER 6: IN VITRO LUNG MODEL MARKET, BY END USERS

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By End Users

    • 6.2. Pharmaceutical And Biotechnology Companies

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Academic And Government Research Institutes

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Contract Research Organizations (CROs)

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

    • 6.5. Others

      • 6.5.1. Key Market Trends, Growth Factors and Opportunities

      • 6.5.2. Market Size and Forecast, By Region

      • 6.5.3. Market Share Analysis, By Country

  • CHAPTER 7: IN VITRO LUNG MODEL MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Type

      • 7.2.3. Market Size and Forecast, By   Application

      • 7.2.4. Market Size and Forecast, By End Users

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S. In Vitro Lung Model Market

        • 7.2.6.1. Market Size and Forecast, By Type
        • 7.2.6.2. Market Size and Forecast, By   Application
        • 7.2.6.3. Market Size and Forecast, By End Users

      • 7.2.7. Canada In Vitro Lung Model Market

        • 7.2.7.1. Market Size and Forecast, By Type
        • 7.2.7.2. Market Size and Forecast, By   Application
        • 7.2.7.3. Market Size and Forecast, By End Users

      • 7.2.8. Mexico In Vitro Lung Model Market

        • 7.2.8.1. Market Size and Forecast, By Type
        • 7.2.8.2. Market Size and Forecast, By   Application
        • 7.2.8.3. Market Size and Forecast, By End Users

    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Type

      • 7.3.3. Market Size and Forecast, By   Application

      • 7.3.4. Market Size and Forecast, By End Users

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France In Vitro Lung Model Market

        • 7.3.6.1. Market Size and Forecast, By Type
        • 7.3.6.2. Market Size and Forecast, By   Application
        • 7.3.6.3. Market Size and Forecast, By End Users

      • 7.3.7. Germany In Vitro Lung Model Market

        • 7.3.7.1. Market Size and Forecast, By Type
        • 7.3.7.2. Market Size and Forecast, By   Application
        • 7.3.7.3. Market Size and Forecast, By End Users

      • 7.3.8. Italy In Vitro Lung Model Market

        • 7.3.8.1. Market Size and Forecast, By Type
        • 7.3.8.2. Market Size and Forecast, By   Application
        • 7.3.8.3. Market Size and Forecast, By End Users

      • 7.3.9. Spain In Vitro Lung Model Market

        • 7.3.9.1. Market Size and Forecast, By Type
        • 7.3.9.2. Market Size and Forecast, By   Application
        • 7.3.9.3. Market Size and Forecast, By End Users

      • 7.3.10. UK In Vitro Lung Model Market

        • 7.3.10.1. Market Size and Forecast, By Type
        • 7.3.10.2. Market Size and Forecast, By   Application
        • 7.3.10.3. Market Size and Forecast, By End Users

      • 7.3.11. Russia In Vitro Lung Model Market

        • 7.3.11.1. Market Size and Forecast, By Type
        • 7.3.11.2. Market Size and Forecast, By   Application
        • 7.3.11.3. Market Size and Forecast, By End Users

      • 7.3.12. Rest Of Europe In Vitro Lung Model Market

        • 7.3.12.1. Market Size and Forecast, By Type
        • 7.3.12.2. Market Size and Forecast, By   Application
        • 7.3.12.3. Market Size and Forecast, By End Users

    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Type

      • 7.4.3. Market Size and Forecast, By   Application

      • 7.4.4. Market Size and Forecast, By End Users

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China In Vitro Lung Model Market

        • 7.4.6.1. Market Size and Forecast, By Type
        • 7.4.6.2. Market Size and Forecast, By   Application
        • 7.4.6.3. Market Size and Forecast, By End Users

      • 7.4.7. Japan In Vitro Lung Model Market

        • 7.4.7.1. Market Size and Forecast, By Type
        • 7.4.7.2. Market Size and Forecast, By   Application
        • 7.4.7.3. Market Size and Forecast, By End Users

      • 7.4.8. India In Vitro Lung Model Market

        • 7.4.8.1. Market Size and Forecast, By Type
        • 7.4.8.2. Market Size and Forecast, By   Application
        • 7.4.8.3. Market Size and Forecast, By End Users

      • 7.4.9. South Korea In Vitro Lung Model Market

        • 7.4.9.1. Market Size and Forecast, By Type
        • 7.4.9.2. Market Size and Forecast, By   Application
        • 7.4.9.3. Market Size and Forecast, By End Users

      • 7.4.10. Australia In Vitro Lung Model Market

        • 7.4.10.1. Market Size and Forecast, By Type
        • 7.4.10.2. Market Size and Forecast, By   Application
        • 7.4.10.3. Market Size and Forecast, By End Users

      • 7.4.11. Thailand In Vitro Lung Model Market

        • 7.4.11.1. Market Size and Forecast, By Type
        • 7.4.11.2. Market Size and Forecast, By   Application
        • 7.4.11.3. Market Size and Forecast, By End Users

      • 7.4.12. Malaysia In Vitro Lung Model Market

        • 7.4.12.1. Market Size and Forecast, By Type
        • 7.4.12.2. Market Size and Forecast, By   Application
        • 7.4.12.3. Market Size and Forecast, By End Users

      • 7.4.13. Indonesia In Vitro Lung Model Market

        • 7.4.13.1. Market Size and Forecast, By Type
        • 7.4.13.2. Market Size and Forecast, By   Application
        • 7.4.13.3. Market Size and Forecast, By End Users

      • 7.4.14. Rest of Asia Pacific In Vitro Lung Model Market

        • 7.4.14.1. Market Size and Forecast, By Type
        • 7.4.14.2. Market Size and Forecast, By   Application
        • 7.4.14.3. Market Size and Forecast, By End Users

    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Type

      • 7.5.3. Market Size and Forecast, By   Application

      • 7.5.4. Market Size and Forecast, By End Users

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil In Vitro Lung Model Market

        • 7.5.6.1. Market Size and Forecast, By Type
        • 7.5.6.2. Market Size and Forecast, By   Application
        • 7.5.6.3. Market Size and Forecast, By End Users

      • 7.5.7. South Africa In Vitro Lung Model Market

        • 7.5.7.1. Market Size and Forecast, By Type
        • 7.5.7.2. Market Size and Forecast, By   Application
        • 7.5.7.3. Market Size and Forecast, By End Users

      • 7.5.8. Saudi Arabia In Vitro Lung Model Market

        • 7.5.8.1. Market Size and Forecast, By Type
        • 7.5.8.2. Market Size and Forecast, By   Application
        • 7.5.8.3. Market Size and Forecast, By End Users

      • 7.5.9. UAE In Vitro Lung Model Market

        • 7.5.9.1. Market Size and Forecast, By Type
        • 7.5.9.2. Market Size and Forecast, By   Application
        • 7.5.9.3. Market Size and Forecast, By End Users

      • 7.5.10. Argentina In Vitro Lung Model Market

        • 7.5.10.1. Market Size and Forecast, By Type
        • 7.5.10.2. Market Size and Forecast, By   Application
        • 7.5.10.3. Market Size and Forecast, By End Users

      • 7.5.11. Rest of LAMEA In Vitro Lung Model Market

        • 7.5.11.1. Market Size and Forecast, By Type
        • 7.5.11.2. Market Size and Forecast, By   Application
        • 7.5.11.3. Market Size and Forecast, By End Users

  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning,2022

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. Epithelix

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. MatTek Corporation

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. Lonza

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. ATCC

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. InSphero

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. Emulate

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. AlveoliX

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. Thermo Fisher Scientific Inc

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

    • 9.9. PromoCell GmbH

      • 9.9.1. Company Overview

      • 9.9.2. Key Executives

      • 9.9.3. Company Snapshot

      • 9.9.4. Operating Business Segments

      • 9.9.5. Product Portfolio

      • 9.9.6. Business Performance

      • 9.9.7. Key Strategic Moves and Developments

    • 9.10. Merck KGaA

      • 9.10.1. Company Overview

      • 9.10.2. Key Executives

      • 9.10.3. Company Snapshot

      • 9.10.4. Operating Business Segments

      • 9.10.5. Product Portfolio

      • 9.10.6. Business Performance

      • 9.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL IN VITRO LUNG MODEL MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL IN VITRO LUNG MODEL MARKET FOR 2D MODELS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL IN VITRO LUNG MODEL MARKET FOR 3D MODELS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL IN VITRO LUNG MODEL MARKET, BY   APPLICATION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL IN VITRO LUNG MODEL MARKET FOR APPLICATIONS OF 2D MODELS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL IN VITRO LUNG MODEL MARKET FOR APPLICATIONS OF 3D MODELS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL IN VITRO LUNG MODEL MARKET, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL IN VITRO LUNG MODEL MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL IN VITRO LUNG MODEL MARKET FOR ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL IN VITRO LUNG MODEL MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL IN VITRO LUNG MODEL MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL IN VITRO LUNG MODEL MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. NORTH AMERICA IN VITRO LUNG MODEL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. NORTH AMERICA IN VITRO LUNG MODEL, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 15. NORTH AMERICA IN VITRO LUNG MODEL, BY   APPLICATION, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA IN VITRO LUNG MODEL, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 17. U.S. IN VITRO LUNG MODEL, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 18. U.S. IN VITRO LUNG MODEL, BY   APPLICATION, 2022-2032 ($MILLION)
  • TABLE 19. U.S. IN VITRO LUNG MODEL, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 20. CANADA IN VITRO LUNG MODEL, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 21. CANADA IN VITRO LUNG MODEL, BY   APPLICATION, 2022-2032 ($MILLION)
  • TABLE 22. CANADA IN VITRO LUNG MODEL, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 23. MEXICO IN VITRO LUNG MODEL, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 24. MEXICO IN VITRO LUNG MODEL, BY   APPLICATION, 2022-2032 ($MILLION)
  • TABLE 25. MEXICO IN VITRO LUNG MODEL, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 26. EUROPE IN VITRO LUNG MODEL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 27. EUROPE IN VITRO LUNG MODEL, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 28. EUROPE IN VITRO LUNG MODEL, BY   APPLICATION, 2022-2032 ($MILLION)
  • TABLE 29. EUROPE IN VITRO LUNG MODEL, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 30. FRANCE IN VITRO LUNG MODEL, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 31. FRANCE IN VITRO LUNG MODEL, BY   APPLICATION, 2022-2032 ($MILLION)
  • TABLE 32. FRANCE IN VITRO LUNG MODEL, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 33. GERMANY IN VITRO LUNG MODEL, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 34. GERMANY IN VITRO LUNG MODEL, BY   APPLICATION, 2022-2032 ($MILLION)
  • TABLE 35. GERMANY IN VITRO LUNG MODEL, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 36. ITALY IN VITRO LUNG MODEL, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 37. ITALY IN VITRO LUNG MODEL, BY   APPLICATION, 2022-2032 ($MILLION)
  • TABLE 38. ITALY IN VITRO LUNG MODEL, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 39. SPAIN IN VITRO LUNG MODEL, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 40. SPAIN IN VITRO LUNG MODEL, BY   APPLICATION, 2022-2032 ($MILLION)
  • TABLE 41. SPAIN IN VITRO LUNG MODEL, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 42. UK IN VITRO LUNG MODEL, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 43. UK IN VITRO LUNG MODEL, BY   APPLICATION, 2022-2032 ($MILLION)
  • TABLE 44. UK IN VITRO LUNG MODEL, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 45. RUSSIA IN VITRO LUNG MODEL, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 46. RUSSIA IN VITRO LUNG MODEL, BY   APPLICATION, 2022-2032 ($MILLION)
  • TABLE 47. RUSSIA IN VITRO LUNG MODEL, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 48. REST OF EUROPE IN VITRO LUNG MODEL, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 49. REST OF EUROPE IN VITRO LUNG MODEL, BY   APPLICATION, 2022-2032 ($MILLION)
  • TABLE 50. REST OF EUROPE IN VITRO LUNG MODEL, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 51. ASIA-PACIFIC IN VITRO LUNG MODEL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 52. ASIA-PACIFIC IN VITRO LUNG MODEL, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 53. ASIA-PACIFIC IN VITRO LUNG MODEL, BY   APPLICATION, 2022-2032 ($MILLION)
  • TABLE 54. ASIA-PACIFIC IN VITRO LUNG MODEL, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 55. CHINA IN VITRO LUNG MODEL, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 56. CHINA IN VITRO LUNG MODEL, BY   APPLICATION, 2022-2032 ($MILLION)
  • TABLE 57. CHINA IN VITRO LUNG MODEL, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 58. JAPAN IN VITRO LUNG MODEL, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 59. JAPAN IN VITRO LUNG MODEL, BY   APPLICATION, 2022-2032 ($MILLION)
  • TABLE 60. JAPAN IN VITRO LUNG MODEL, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 61. INDIA IN VITRO LUNG MODEL, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 62. INDIA IN VITRO LUNG MODEL, BY   APPLICATION, 2022-2032 ($MILLION)
  • TABLE 63. INDIA IN VITRO LUNG MODEL, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 64. SOUTH KOREA IN VITRO LUNG MODEL, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 65. SOUTH KOREA IN VITRO LUNG MODEL, BY   APPLICATION, 2022-2032 ($MILLION)
  • TABLE 66. SOUTH KOREA IN VITRO LUNG MODEL, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 67. AUSTRALIA IN VITRO LUNG MODEL, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 68. AUSTRALIA IN VITRO LUNG MODEL, BY   APPLICATION, 2022-2032 ($MILLION)
  • TABLE 69. AUSTRALIA IN VITRO LUNG MODEL, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 70. THAILAND IN VITRO LUNG MODEL, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 71. THAILAND IN VITRO LUNG MODEL, BY   APPLICATION, 2022-2032 ($MILLION)
  • TABLE 72. THAILAND IN VITRO LUNG MODEL, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 73. MALAYSIA IN VITRO LUNG MODEL, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 74. MALAYSIA IN VITRO LUNG MODEL, BY   APPLICATION, 2022-2032 ($MILLION)
  • TABLE 75. MALAYSIA IN VITRO LUNG MODEL, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 76. INDONESIA IN VITRO LUNG MODEL, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 77. INDONESIA IN VITRO LUNG MODEL, BY   APPLICATION, 2022-2032 ($MILLION)
  • TABLE 78. INDONESIA IN VITRO LUNG MODEL, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 79. REST OF ASIA PACIFIC IN VITRO LUNG MODEL, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 80. REST OF ASIA PACIFIC IN VITRO LUNG MODEL, BY   APPLICATION, 2022-2032 ($MILLION)
  • TABLE 81. REST OF ASIA PACIFIC IN VITRO LUNG MODEL, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 82. LAMEA IN VITRO LUNG MODEL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 83. LAMEA IN VITRO LUNG MODEL, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 84. LAMEA IN VITRO LUNG MODEL, BY   APPLICATION, 2022-2032 ($MILLION)
  • TABLE 85. LAMEA IN VITRO LUNG MODEL, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 86. BRAZIL IN VITRO LUNG MODEL, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 87. BRAZIL IN VITRO LUNG MODEL, BY   APPLICATION, 2022-2032 ($MILLION)
  • TABLE 88. BRAZIL IN VITRO LUNG MODEL, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 89. SOUTH AFRICA IN VITRO LUNG MODEL, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 90. SOUTH AFRICA IN VITRO LUNG MODEL, BY   APPLICATION, 2022-2032 ($MILLION)
  • TABLE 91. SOUTH AFRICA IN VITRO LUNG MODEL, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 92. SAUDI ARABIA IN VITRO LUNG MODEL, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 93. SAUDI ARABIA IN VITRO LUNG MODEL, BY   APPLICATION, 2022-2032 ($MILLION)
  • TABLE 94. SAUDI ARABIA IN VITRO LUNG MODEL, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 95. UAE IN VITRO LUNG MODEL, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 96. UAE IN VITRO LUNG MODEL, BY   APPLICATION, 2022-2032 ($MILLION)
  • TABLE 97. UAE IN VITRO LUNG MODEL, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 98. ARGENTINA IN VITRO LUNG MODEL, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 99. ARGENTINA IN VITRO LUNG MODEL, BY   APPLICATION, 2022-2032 ($MILLION)
  • TABLE 100. ARGENTINA IN VITRO LUNG MODEL, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 101. REST OF LAMEA IN VITRO LUNG MODEL, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 102. REST OF LAMEA IN VITRO LUNG MODEL, BY   APPLICATION, 2022-2032 ($MILLION)
  • TABLE 103. REST OF LAMEA IN VITRO LUNG MODEL, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 104. EPITHELIX: KEY EXECUTIVES
  • TABLE 105. EPITHELIX: COMPANY SNAPSHOT
  • TABLE 106. EPITHELIX: OPERATING SEGMENTS
  • TABLE 107. EPITHELIX: PRODUCT PORTFOLIO
  • TABLE 108. EPITHELIX: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 109. MATTEK CORPORATION: KEY EXECUTIVES
  • TABLE 110. MATTEK CORPORATION: COMPANY SNAPSHOT
  • TABLE 111. MATTEK CORPORATION: OPERATING SEGMENTS
  • TABLE 112. MATTEK CORPORATION: PRODUCT PORTFOLIO
  • TABLE 113. MATTEK CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 114. LONZA: KEY EXECUTIVES
  • TABLE 115. LONZA: COMPANY SNAPSHOT
  • TABLE 116. LONZA: OPERATING SEGMENTS
  • TABLE 117. LONZA: PRODUCT PORTFOLIO
  • TABLE 118. LONZA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 119. ATCC: KEY EXECUTIVES
  • TABLE 120. ATCC: COMPANY SNAPSHOT
  • TABLE 121. ATCC: OPERATING SEGMENTS
  • TABLE 122. ATCC: PRODUCT PORTFOLIO
  • TABLE 123. ATCC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 124. INSPHERO: KEY EXECUTIVES
  • TABLE 125. INSPHERO: COMPANY SNAPSHOT
  • TABLE 126. INSPHERO: OPERATING SEGMENTS
  • TABLE 127. INSPHERO: PRODUCT PORTFOLIO
  • TABLE 128. INSPHERO: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 129. EMULATE: KEY EXECUTIVES
  • TABLE 130. EMULATE: COMPANY SNAPSHOT
  • TABLE 131. EMULATE: OPERATING SEGMENTS
  • TABLE 132. EMULATE: PRODUCT PORTFOLIO
  • TABLE 133. EMULATE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 134. ALVEOLIX: KEY EXECUTIVES
  • TABLE 135. ALVEOLIX: COMPANY SNAPSHOT
  • TABLE 136. ALVEOLIX: OPERATING SEGMENTS
  • TABLE 137. ALVEOLIX: PRODUCT PORTFOLIO
  • TABLE 138. ALVEOLIX: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 139. THERMO FISHER SCIENTIFIC INC: KEY EXECUTIVES
  • TABLE 140. THERMO FISHER SCIENTIFIC INC: COMPANY SNAPSHOT
  • TABLE 141. THERMO FISHER SCIENTIFIC INC: OPERATING SEGMENTS
  • TABLE 142. THERMO FISHER SCIENTIFIC INC: PRODUCT PORTFOLIO
  • TABLE 143. THERMO FISHER SCIENTIFIC INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 144. PROMOCELL GMBH: KEY EXECUTIVES
  • TABLE 145. PROMOCELL GMBH: COMPANY SNAPSHOT
  • TABLE 146. PROMOCELL GMBH: OPERATING SEGMENTS
  • TABLE 147. PROMOCELL GMBH: PRODUCT PORTFOLIO
  • TABLE 148. PROMOCELL GMBH: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 149. MERCK KGAA: KEY EXECUTIVES
  • TABLE 150. MERCK KGAA: COMPANY SNAPSHOT
  • TABLE 151. MERCK KGAA: OPERATING SEGMENTS
  • TABLE 152. MERCK KGAA: PRODUCT PORTFOLIO
  • TABLE 153. MERCK KGAA: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL IN VITRO LUNG MODEL MARKET SEGMENTATION
  • FIGURE 2. GLOBAL IN VITRO LUNG MODEL MARKET
  • FIGURE 3. SEGMENTATION IN VITRO LUNG MODEL MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN IN VITRO LUNG MODEL MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALIN VITRO LUNG MODEL MARKET
  • FIGURE 11. IN VITRO LUNG MODEL MARKET SEGMENTATION, BY BY TYPE
  • FIGURE 12. IN VITRO LUNG MODEL MARKET FOR 2D MODELS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. IN VITRO LUNG MODEL MARKET FOR 3D MODELS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. IN VITRO LUNG MODEL MARKET SEGMENTATION, BY BY   APPLICATION
  • FIGURE 15. IN VITRO LUNG MODEL MARKET FOR APPLICATIONS OF 2D MODELS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. IN VITRO LUNG MODEL MARKET FOR APPLICATIONS OF 3D MODELS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. IN VITRO LUNG MODEL MARKET SEGMENTATION, BY BY END USERS
  • FIGURE 18. IN VITRO LUNG MODEL MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. IN VITRO LUNG MODEL MARKET FOR ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 20. IN VITRO LUNG MODEL MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 21. IN VITRO LUNG MODEL MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 22. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 23. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 24. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 25. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 26. COMPETITIVE DASHBOARD
  • FIGURE 27. COMPETITIVE HEATMAP: IN VITRO LUNG MODEL MARKET
  • FIGURE 28. Top player positioning, 2022
  • FIGURE 29. EPITHELIX: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 30. EPITHELIX: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 31. EPITHELIX: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 32. MATTEK CORPORATION: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 33. MATTEK CORPORATION: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 34. MATTEK CORPORATION: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 35. LONZA: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 36. LONZA: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 37. LONZA: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 38. ATCC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 39. ATCC: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 40. ATCC: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 41. INSPHERO: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 42. INSPHERO: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 43. INSPHERO: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 44. EMULATE: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 45. EMULATE: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 46. EMULATE: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 47. ALVEOLIX: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 48. ALVEOLIX: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 49. ALVEOLIX: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 50. THERMO FISHER SCIENTIFIC INC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 51. THERMO FISHER SCIENTIFIC INC: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 52. THERMO FISHER SCIENTIFIC INC: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 53. PROMOCELL GMBH: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 54. PROMOCELL GMBH: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 55. PROMOCELL GMBH: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 56. MERCK KGAA: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 57. MERCK KGAA: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 58. MERCK KGAA: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now
RELATED TAGS

Purchase Full Report of
In Vitro Lung Model Market

Start reading.
This Report and over 66,905+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers